Skip to main content

Table 5 Lipid profile of children on lipid-lowering treatment

From: Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry

Parameter Children
Statin ± Ezetimibe
(n = 57)
Pre-treatment Post-treatment
Total cholesterol, mg/dL
(mmol/L)
322 ± 81
(8.3 ± 2.1)
233 ± 133§
(6.0 ± 3.4)§
Triglycerides, mg/dL
(mmol/L)
77 (53–105)
[0.9 (0.6–1.2)]
66 (53–89)
[0.7 (0.6–1.0)]
HDL-C, mg/dL
(mmol/L)
54 ± 14
(1.4 ± 0.4)
52 ± 12
(1.3 ± 0.3)
non-HDL-C, mg/dL
(mmol/L)
268 ± 81
(6.9 ± 2.1)
180 ± 136§
(4.7 ± 35) §
LDL-CF, mg/dL
(mmol/L)
251 ± 79
(6.5 ± 2.0)
148 ± 58§
(3.8 ± 1.5) §
LDL-CM/H, mg/dL
(mmol/L)
248 ± 79
(6.4 ± 2.0)
146 ± 57§
(3.8 ± 1.5)§
aLDL-CLp(a)corM/H, mg/dL
(mmol/L)
253 ± 88
(6.5 ± 2.3)
125 ± 54†,§,§§
(3.2 ± 1.4)§,§§
aLp(a), mg/dL
(nmol/L)
21 (6–86)
[42.0 (9.3–183.7)]
21 (9–61)
[42.0 (15.8–129.2)]
  1. Data are presented as mean ± standard deviation or median (interquartile range) for parametric and non-parametric variables, respectively
  2. HDL-C High-density lipoprotein cholesterol, LDL-CF Low-density lipoprotein cholesterol as calculated by the Friedewald formula, LDL-CM/H Low-density lipoprotein cholesterol as calculated by the Marin/Hopkins formula, LDL-CLp(a)corM/H Corrected for Lp(a) levels low-density lipoprotein cholesterol as calculated by the Marin/Hopkins formula, PCKS9i Proprotein convertase subtilisin/kexin type 9 inhibitor, Lp(a) was converted using the formula: Lp(a) nmol/L = 2.18 × Lp(a) mg/dL − 3.83
  3. : P < 0.001 vs LDL-CF, §P < 0.001 vs pre-treatment, §§P < 0.001 for the comparison of LDL-C change compared with the change of LDL-CF and LDL-CM/H
  4. a: Data available for 40 patients